14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AVDL vs SUPN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Supernus Pharmaceuticals, Inc. (SUPN) on higher Unified Composite conviction (62.9/100 BUY vs. 54.3/100 HOLD) after splitting the core matrix 6–4 (led by Options & Positioning), while SUPN wins 5–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus SUPN at $28.61 (7.2x Forward P/E, 46.9% operating margin).
Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. SUPN 54.3/100 HOLD) and 0.14β · 2% Vol risk profile, whereas SUPN leads top-line expansion (+13.4% YoY revenue growth, 1.47x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile SUPN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs SUPN. Trailing 12-month operating profitability (AVDL 2.5% vs SUPN 46.9%) and valuation multiples (AVDL 28.8x vs SUPN 7.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
SUPN Moat ProfileHigh-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $5.9B market capitalization and 46.9% operating margin.
OpEx & R&D Reinvestment38.8% of Rev ($533M)
90D Engineering Disclosures0 Published
Investor FAQ AVDL vs SUPN Key Questions & Quantitative Answers
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Supernus Pharmaceuticals, Inc. (SUPN) on higher Unified Composite conviction (62.9/100 BUY vs. 54.3/100 HOLD) after splitting the core matrix 6–4 (led by Options & Positioning), while SUPN wins 5–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus SUPN at $28.61 (7.2x Forward P/E, 46.9% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. SUPN 54.3/100 HOLD) and 0.14β · 2% Vol risk profile, whereas SUPN leads top-line expansion (+13.4% YoY revenue growth, 1.47x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile SUPN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SUPN leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with SUPN at +13.4% YoY revenue growth and +239.4% YoY earnings growth on $1.37B TTM revenue (85.7% gross margin, 46.9% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $1.37B for SUPN. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($533M) (0 disclosures) for SUPN.
SUPN screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas SUPN trades at 7.2x Forward P/E, 20.2x Trailing P/E, 1.47x PEG, and 4.2x EV/Revenue (6.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus SUPN (-4.2% ROE) capital efficiency.
In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, SUPN carries 38.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.79x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.64β · 120% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.